Novartis has stopped work on a gene therapy candidate it acquired a little under two years ago, according to an investor in the company the Swiss drugmaker bought.
The decision to discontinue research follows a recommendation from a data monitoring committee overseeing testing of the therapy, known as GT005 and for the eye condition geographic atrophy. After reviewing available data, including from a Phase 2 study, the group concluded development shouldn’t move forward.
